º£½ÇÉçÇø

The Division of Cardiac Surgery excels in basic science, clinical research, and surgical education, driving advancements in cardiac and transplant surgery. Dr. Jayan Nagendran and Dr. Darren Freed lead research in Ex-Situ Heart and Lung Perfusion (ESLP), a technology that extends donor organ viability by maintaining metabolic and oxygen support during transport.
Dr. Jeevan Nagendran heads Tissue-Engineered Heart Valve (TEHV) research, using mesenchymal stem cells to enhance bioprosthetic valve durability and prevent xenogenic immune rejection.

The division actively conducts high-impact clinical trials, including TitanSVS, TRAC-AF, STICH3C, BEEFBURGER, LeAAPS, DANCE, SAFE, PACeS, PREDICT-TAA, TIARA-I, DARTS1, PROTECT, TR, ROMA: Women, HEADSTART, and ARTEMIS.

Committed to training future surgeon-scientists, several residents pursue PhD research in advanced cardiac techniques. Dr. Jimmy Kang and Dr. Ryaan El-Andari are completing PhDs in TEHV and ESLP, respectively. Through innovative research, clinical excellence, and education, the division continues to shape the future of cardiac and transplant surgery.